PSMA imaging is central to treatment selection
Heidelberg describes PSMA PET/CT and related imaging as a way to show whether tumor deposits express the target strongly enough for PSMA-directed treatment. A treatment request should therefore include recent molecular imaging when available and should not assume that a rising PSA alone establishes suitability.
Eligibility requires the whole prostate-cancer history
A German nuclear-medicine or uro-oncology team needs to understand prior systemic therapy, response, progression and current disease burden before deciding whether radioligand therapy belongs in the sequence.
- Pathology and prostate-cancer diagnosis
- Current stage and sites of metastases
- PSMA PET/CT images and report when available
- Prior hormone treatments
- Prior chemotherapy and other systemic treatments
- Previous radiotherapy or surgery
- Recent blood count and kidney/liver function
- Current symptoms and performance status
Treatment is delivered in cycles, not as one isolated injection
Heidelberg describes repeated treatment cycles with interval laboratory monitoring. The number of cycles and whether treatment continues depend on response, tolerance and the specialist plan.
Coordinate nuclear medicine with uro-oncology
If the right point in the treatment sequence is unclear, Heidelberg advises multidisciplinary evaluation rather than treating nuclear medicine as a substitute for broader prostate-cancer management.
International travel planning
Ask how long each treatment visit requires, what radiation-safety instructions apply after discharge, which blood tests are needed between cycles and whether imaging or oncology follow-up can be performed in the home country.
Official sources
Sources last checked 2026-09-07.